Your browser doesn't support javascript.
loading
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
Corbett, Kizzmekia S; Edwards, Darin; Leist, Sarah R; Abiona, Olubukola M; Boyoglu-Barnum, Seyhan; Gillespie, Rebecca A; Himansu, Sunny; Schäfer, Alexandra; Ziwawo, Cynthia T; DiPiazza, Anthony T; Dinnon, Kenneth H; Elbashir, Sayda M; Shaw, Christine A; Woods, Angela; Fritch, Ethan J; Martinez, David R; Bock, Kevin W; Minai, Mahnaz; Nagata, Bianca M; Hutchinson, Geoffrey B; Bahl, Kapil; Garcia-Dominguez, Dario; Ma, LingZhi; Renzi, Isabella; Kong, Wing-Pui; Schmidt, Stephen D; Wang, Lingshu; Zhang, Yi; Stevens, Laura J; Phung, Emily; Chang, Lauren A; Loomis, Rebecca J; Altaras, Nedim Emil; Narayanan, Elisabeth; Metkar, Mihir; Presnyak, Vlad; Liu, Catherine; Louder, Mark K; Shi, Wei; Leung, Kwanyee; Yang, Eun Sung; West, Ande; Gully, Kendra L; Wang, Nianshuang; Wrapp, Daniel; Doria-Rose, Nicole A; Stewart-Jones, Guillaume; Bennett, Hamilton; Nason, Martha C; Ruckwardt, Tracy J.
Afiliación
  • Corbett KS; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Edwards D; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Leist SR; Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill, North Carolina, 27599; United States of America.
  • Abiona OM; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Boyoglu-Barnum S; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Gillespie RA; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Himansu S; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Schäfer A; Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill, North Carolina, 27599; United States of America.
  • Ziwawo CT; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • DiPiazza AT; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Dinnon KH; Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill, North Carolina, 27599; United States of America.
  • Elbashir SM; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Shaw CA; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Woods A; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Fritch EJ; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill; Chapel Hill, North Carolina, 27599; United States of America.
  • Martinez DR; Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill, North Carolina, 27599; United States of America.
  • Bock KW; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Minai M; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Nagata BM; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Hutchinson GB; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Bahl K; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Garcia-Dominguez D; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Ma L; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Renzi I; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Kong WP; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Schmidt SD; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Wang L; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Zhang Y; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Stevens LJ; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, 37212; United States of America.
  • Phung E; Institute for Biomedical Sciences, George Washington University, Washington, DC 20052, United States of America.
  • Chang LA; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Loomis RJ; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Altaras NE; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Narayanan E; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Metkar M; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Presnyak V; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Liu C; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Louder MK; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Shi W; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Leung K; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Yang ES; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • West A; Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill, North Carolina, 27599; United States of America.
  • Gully KL; Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill, North Carolina, 27599; United States of America.
  • Wang N; Department of Molecular Biosciences; University of Texas at Austin; Austin, Texas, 78712; United States of America.
  • Wrapp D; Department of Molecular Biosciences; University of Texas at Austin; Austin, Texas, 78712; United States of America.
  • Doria-Rose NA; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Stewart-Jones G; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Bennett H; Moderna Inc., Cambridge, MA, 02139; United States of America.
  • Nason MC; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
  • Ruckwardt TJ; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.
bioRxiv ; 2020 Jun 11.
Article en En | MEDLINE | ID: mdl-32577634
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: BioRxiv Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: BioRxiv Año: 2020 Tipo del documento: Article